Price movement over the last 24 hours
Global X MSCI Argentina ETF vs Zoetis Inc — how do they compare? Global X MSCI Argentina ETF trades at $95.07, while Zoetis Inc trades at $75.97 (market cap $31.68B). The key difference: Zoetis Inc pays a 2.81% dividend while Global X MSCI Argentina ETF pays none, and Global X MSCI Argentina ETF is trading nearer its 52-week high, Zoetis Inc nearer its low. Which is the better fit depends on your goals.
| ARGT | ZTS | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $102.94 | $156.76 |
52-Week Low | $67.55 | $71.91 |
Market Cap | — | $31.68B |
Enterprise Value | — | $38.97B |
Dividend Yield | — | 2.81% |
Signals from Pluang's Aura AI — not financial advice
ARGT (Global X MSCI Argentina ETF) trades at $95.07, up 3.08% with a neutral technical signal. The ETF shows bullish moving averages but mixed oscillators, with support at $92 and resistance at $93. Recent positive sentiment stems from Argentina's economic reforms under the Milei Administration, with Seeking Alpha upgrading the rating to buy citing 28% upside potential based on valuation re-rating opportunities.
The outlook appears constructive given Argentina's improving macroeconomic backdrop, though concentration risk in MercadoLibre and ongoing economic transition pose challenges. Wall Street sentiment has turned positive with institutional accumulation noted, but investors should monitor fiscal stabilization progress and inflation trends for sustained momentum.
Zoetis (ZTS) trades at $75.56, up 0.64% with a bearish technical signal despite strong fundamentals. The company maintains robust profitability with 28.03% net margins and 67.75% ROE, supported by consistent revenue growth to $9.47B in 2025. Recent Q1 2026 earnings missed expectations, but analyst consensus remains positive with a $101.43 price target. Legal developments include multiple securities class action notices with July 27, 2026 deadlines.
ZTS presents a mixed outlook with strong fundamental performance offset by technical weakness and legal overhangs. The stock trades at attractive valuations (P/E 12.39) with significant upside to analyst targets, but investors face near-term volatility from the class action proceedings and recent earnings miss. Long-term growth prospects remain solid given the company's market leadership in animal health.
Trailing returns across standard periods
Latest headlines on both assets
ARGT seeks to provide investment results that correspond to the performance of the MSCI All Argentina 25/50 Index. It offers targeted exposure to some of the largest and most liquid companies operating in Argentina.
Read more on ARGT →Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →